← FDA DRUG APPROVALS

FDA ANDA · ANDA217192

EPINEPHRINE

Sponsor: AM REGENT

APPLICATION
ANDA217192
TYPE
ANDA
ORIGINAL APPROVAL
2024-09-06
LATEST ACTION
2024-09-06
ROUTE
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

EPINEPHRINEPrescription
EPINEPHRINE EQ 30MG BASE/30ML (EQ 1MG BASE/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Approval history

2024-09-06UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →